Abstract:Background: Plasminogen activator inhibitor-1 (PAI-1) has been regarded as a risk factor for thrombosis and atherosclerosis. Since it has been shown that PAI-1 can activate macrophages through Toll-like receptor-4, we sought to investigate the role of PAI-1 in the tumor microenvironment. Methods: The expression and distribution patterns of PAI-1 and transforming growth factor beta (TGF-β) were measured in 60 non-small cell lung cancer (NSCLC) tumors. A statistical correlation analysis was performed between PAI-1 and TGF-β expression and distribution in each tumor. The distribution of tumor-associated macrophages (TAMs) was also measured and its correlation to PAI-1 levels was analyzed. Levels of secreted CCL-17, CCL-22, IL-6 and TGF-β were measured in cell cultures of human macrophage cell lines THP-1 and U937 treated with PAI-1. Levels of secreted PAI-1 were monitored in cell cultures of human NSCLCs cell lines 95D and A549 treated with TGF-β. Secreted proteins were measured in cell culture supernatants using ELISA. Changes in downstream signaling pathways were investigated using western blot. Results: PAI-1 and TGF-β were found to be overexpressed in human NSCLCs. PAI-1 expression was tightly correlated to TGF-β expression as well as the percentage of TAMs. PAI-1 treatment increased the expression of TAM-associated cytokines and chemokines, including CCL-17, CCL-22, and IL-6. PAI-1 treatment was also observed to enhance TGF-β expression in macrophage cell lines through an IL-6 autocrine/paracrine manner. The effects on TGF-β expression were blocked by NF-κB and STAT3 inhibition. Interestingly, TGF-β also increased levels of secreted PAI-1 in NSCLC cells through SMAD3-dependent signaling, therefore resulting in a feed-forward loop. However, this loop could be blocked by NF-κB, STAT3 and SMAD3 signaling inhibition, as well as treatment with a high concentration of TGF-β. Conclusion: PAI-1 and TGF-β promote NSCLC tumor cells and TAMs and might be valuable targets for cancer immunosuppression.

Development about Effects and Mechanisms of PAI-1 in Tumor Angiogenesis

Plasminogen Activator Inhibitor-1 in Cancer Research.

Research Progress in Tumor Therapy Targeting Plasminogen Activator Inhibitor-1

Research Progress of Plasminogen Activator Inhibitor-1 in Several Diseases

Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors

Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.

Plasminogen Activator Inhibitor-1 Inhibits Angiogenic Signaling by Uncoupling Vascular Endothelial Growth Factor Receptor-2-α V Β 3 Integrin Cross Talk

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1

Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-Β1 Expression in Macrophage

[Inhibitor of Plasminogen Activator 1 (PAI-1) in Hepatocellular Carcinoma].

Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis

Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer

Recombinant Plasminogen Activator Inhibitor-1 Inhibits Intimal Hyperplasia

Targeting Plasminogen Activator Inhibitor-1 to Prevent Vascular Disease

Inhibition of PAI-1: a new anti-thrombotic approach.

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo

Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin.

Advances of Sphingosine-1-phosphate in Angiogenesis

Role of Paip1 on Angiogenesis and Invasion in Pancreatic Cancer

Protein Microarrays for Quantitative Detection of Pai-1 in Serum